Opinion|Videos|July 10, 2024
Exploring Toxicities for Second Line Treatments in mCRC
The panel examines prevalent adverse events experienced by patients receiving second-line biomarker-directed therapy for metastatic colorectal cancer.
Advertisement
Episodes in this series
- Briefly discuss common AEs for patients treated with 2L biomarker-directed therapy for mCRC.
- What similarities and differences can be observed based on specific clinically actionable targets?
- What strategies have you explored to mitigate and manage those events?
- Dr Marshall: Based on the following data updates presented in mCRC, how does this impact the future treatment landscape in the second line setting?
Advertisement
Related to this article
The FDA granted fast track designation to opamtistomig for first-line treatment of advanced or metastatic biliary tract cancer.
A planned interim analysis of the radiopharmaceutical RYZ101 showed improved PFS by blinded independent central review vs standard of care.
The top 5 OncLive TV videos of the week.
Check out this September recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.
Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Advertisement
Advertisement
Trending on OncLive
1
Dr Fradley on Real-World Atrial Fibrillation and Cardiovascular Outcomes in CLL
2
Poll Results Highlight Breast Cancer Abstracts of Interest at ESMO 2026
3
FDA Grants Fast Track Designation to Opamtistomig for Advanced Biliary Tract Cancer
4
Dr Hansen on the Integration of CAR T-Cell Therapy Into Earlier Myeloma Treatment Lines
5